01:04 PM EDT, 05/15/2024 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) said Wednesday that its second phase 3 study of tradipitant in motion sickness yielded "positive" results.

The results of the study, conducted in real-world conditions on boats in US coastal waters, confirmed the previously reported results of two efficacy studies showing the effectiveness of tradipitant in preventing vomiting associated with motion sickness, the company said.

The company said it expects to submit a new drug application for tradipitant in the prevention of motion-induced vomiting to the US Food and Drug Administration in Q4.

Vanda shares rose 4.5% in recent trading.

Price: 5.36, Change: +0.23, Percent Change: +4.50